Aurobindo Pharma shares in focus after UK arm secures regulatory approval for cancer drug

Aurobindo Pharma shares rose 2% to Rs 1,265 on BSE after CuraTeQ Biologics received UK MHRA approval for Bevgolva, a biosimilar of bevacizumab for treating multiple cancers. The drug will be available in 4 mL and 16 mL vials for intravenous use, also indicated for non-squamous non-small cell lung cancer, advanced renal cell carcinoma, cervical cancer, and ovarian-related cancers.